What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Breast cancer
Aron Goldhirsch mainly focuses on Internal medicine, Breast cancer, Oncology, Surgery and Chemotherapy.
Internal medicine is represented through his Tamoxifen, Randomized controlled trial, Trastuzumab, Clinical endpoint and Clinical trial research.
His work carried out in the field of Breast cancer brings together such families of science as Cyclophosphamide and Disease.
His Oncology study combines topics from a wide range of disciplines, such as Cancer, Adjuvant therapy, Gynecology and Hazard ratio.
His studies in Surgery integrate themes in fields like Adverse effect, Intensive care medicine, Lymph node and Axilla.
Within one scientific family, he focuses on topics pertaining to Anthracycline under Chemotherapy, and may sometimes address concerns connected to Methotrexate, Pathological, Rate ratio, Epirubicin and Docetaxel.
His most cited work include:
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (4015 citations)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
- A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer (1326 citations)
What are the main themes of his work throughout his whole career to date?
Aron Goldhirsch mostly deals with Internal medicine, Breast cancer, Oncology, Chemotherapy and Cancer.
His research investigates the connection between Internal medicine and topics such as Surgery that intersect with problems in Gastroenterology.
As a part of the same scientific family, Aron Goldhirsch mostly works in the field of Breast cancer, focusing on Gynecology and, on occasion, Hormone therapy.
His Oncology research focuses on Cyclophosphamide and how it relates to Fluorouracil.
His research in Chemotherapy intersects with topics in Regimen, Methotrexate, Adverse effect and Anthracycline.
His Cancer research incorporates themes from Carcinoma, Pathology and Immunology.
He most often published in these fields:
- Internal medicine (76.04%)
- Breast cancer (68.22%)
- Oncology (63.81%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (76.04%)
- Breast cancer (68.22%)
- Oncology (63.81%)
In recent papers he was focusing on the following fields of study:
Aron Goldhirsch spends much of his time researching Internal medicine, Breast cancer, Oncology, Tamoxifen and Chemotherapy.
His studies in Randomized controlled trial, Hazard ratio, Letrozole, Clinical endpoint and Adjuvant are all subfields of Internal medicine research.
The study incorporates disciplines such as Clinical trial, Gynecology and Endocrine system in addition to Breast cancer.
His Oncology research integrates issues from Cancer, Pathological, Trastuzumab, Adverse effect and Proportional hazards model.
His Exemestane and Aromatase inhibitor study, which is part of a larger body of work in Tamoxifen, is frequently linked to Single-nucleotide polymorphism, bridging the gap between disciplines.
The concepts of his Chemotherapy study are interwoven with issues in Meta-analysis and Methotrexate.
Between 2014 and 2021, his most popular works were:
- Adjuvant ovarian suppression in premenopausal breast cancer (418 citations)
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (362 citations)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (293 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
His primary areas of study are Internal medicine, Breast cancer, Oncology, Chemotherapy and Hazard ratio.
Aron Goldhirsch specializes in Breast cancer, namely Estrogen receptor.
The Oncology study combines topics in areas such as Pembrolizumab, Cancer, Adjuvant therapy, Gynecology and Radiation therapy.
His research integrates issues of Triple Negative Breast Neoplasms and Methotrexate in his study of Chemotherapy.
His Hazard ratio study which covers Mastectomy that intersects with Sentinel node, Axilla and Population study.
His studies deal with areas such as Survival analysis and Trastuzumab as well as Clinical endpoint.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
